Referencia número: HY-19296

BDCRB

Name: BDCRB
Brand: MedChemExpress
SKU: HY-19296
Availability: PreOrder

(Synonyms: 2-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole)

BDCRB is a selective Human cytomegalovirus (HCMV) inhibitor through blocking the maturational cleavage of high-molecular-weight DNA. BDCRB shows a mean IC₅₀ of 0.03 μM for viral yield at 72 h postinfection.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS: 142356-43-2
Fòrmula: C₁₂H₁₁BrCl₂N₂O₄
Peso molecular:398.04

Almacenamiento:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

BDCRB Chemical Structure

No. CAS: 142356-43-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- Cellular Effect
Chemical Information
Protocolo (1)
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	IC₅₀	130 μM Compound: BDCRB (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509174]
BSC-1	IC₅₀	130 μM Compound: BDCRB (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509175]
BSC-1	IC₅₀	130 μM Compound: BDCRB (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509176]
carcinoma cell line	IC₅₀	>100 μM Compound: 5	Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay. Compound was tested for inhibition activity of human oral carcinoma cell line (KB ) cells in quadruplicate assay.	[PMID: 10882375]
HFF	CC₅₀	313.6 μM Compound: BDCRB	Cytotoxicity against HFF after 8 days by XTT assay Cytotoxicity against HFF after 8 days by XTT assay	[PMID: 19786605]
HFF	IC₅₀	0.3 μM Compound: 4b	Compound was tested for antiviral activity against wild-type Towne virus of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against wild-type Towne virus of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.34 μM Compound: 4b	Compound was tested for antiviral activity against wild-type AD169 virus of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against wild-type AD169 virus of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.41 μM Compound: 4b	Compound was tested for antiviral activity against 2916 strain of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against 2916 strain of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.7 μM Compound: 4b	Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	0.7 μM Compound: 5	Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells	[PMID: 10882375]
HFF	IC₅₀	0.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509174]
HFF	IC₅₀	0.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509175]
HFF	IC₅₀	0.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	0.99 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	1.7 μM Compound: 4b	Compound was tested for antiviral activity against wild-type Towne virus of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against wild-type Towne virus of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	118 μM Compound: 1b (BDCRB)	Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination	[PMID: 15509173]
HFF	IC₅₀	118 μM Compound: 4b	Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration	[PMID: 10882374]
HFF	IC₅₀	118 μM Compound: BDCRB (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509174]
HFF	IC₅₀	118 μM Compound: BDCRB (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509175]
HFF	IC₅₀	118 μM Compound: BDCRB (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509176]
HFF	IC₅₀	118 μM Compound: 5	Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells Compound was tested for visual cytotoxicity on human foreskin fibroblasts (HFF) cells	[PMID: 10882375]
HFF	IC₅₀	12 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	29 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	31 μM Compound: 4b	Compound was tested for antiviral activity against C-4 Towne virus of HCMV in plaque reduction assay using HFF cells Compound was tested for antiviral activity against C-4 Towne virus of HCMV in plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	6.7 μM Compound: BDCRB (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	8 μM Compound: 4b	Compound was tested for antiviral activity against C-4 Towne virus of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against C-4 Towne virus of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
KB	IC₅₀	>100 μM Compound: 1b (BDCRB)	Concentration required to inhibit KB cell line growth was determined by crystal violet staining method Concentration required to inhibit KB cell line growth was determined by crystal violet staining method	[PMID: 15509173]
KB	IC₅₀	>100 μM Compound: BDCRB (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509174]
KB	IC₅₀	>100 μM Compound: BDCRB (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509175]
KB	IC₅₀	>100 μM Compound: BDCRB (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509176]
KB	IC₅₀	>100 μM Compound: 4b	Compound was tested for inhibition of KB cell growth in quadruplicate assay Compound was tested for inhibition of KB cell growth in quadruplicate assay	[PMID: 10882374]
NIH3T3	CC₅₀	88.1 μM Compound: BDCRB	Cytotoxicity against mouse NIH/3T3 cells after 8 days by XTT assay Cytotoxicity against mouse NIH/3T3 cells after 8 days by XTT assay	[PMID: 19786605]

Chemical Information

No. CAS 142356-43-2
Peso molecular 398.04
Fòrmula C₁₂H₁₁BrCl₂N₂O₄
SMILES

O[C@H]1[C@H](N2C3=CC(Cl)=C(Cl)C=C3N=C2Br)O[C@H](CO)[C@H]1O
Synonyms

2-Bromo-5,6-dichloro-1-β-D-ribofuranosyl benzimidazole
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocolo

All Cell Biology

Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (269 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72. [Content Brief]

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

BDCRB

Actividad biológica

Descripciòn

Cellular Effect

Chemical Information

Protocolo

Pureza y Documentación

Referencias

Calculators

Help & FAQs

Bioz

Keywords

Your Recently Viewed Products

BDCRB

Actividad biológica

Descripciòn

Cellular Effect

Chemical Information

Protocolo

Pureza y Documentación

Referencias

Calculators

Help & FAQs

BDCRB Related Classifications

HY-19296 Related Classifications

Bioz

Keywords

Your Recently Viewed Products